KPV: The Definitive Guide

What is KPV?

KPV is a lab-made peptide made of three amino acids: lysine (K), proline (P) and valine (V). People inject it or take it as capsules hoping to calm gut, skin or allergy-type inflammation, but it has only been studied in cells and animals, never in people.

The letters are the one-letter codes for its three building blocks, and the chain is so short that it is one of the smallest peptides sold. Its sequence matches the last three amino acids of alpha-MSH (alpha-melanocyte-stimulating hormone), a 13-amino-acid hormone the body makes, so older research calls it "alpha-MSH (11-13)". [1], [2], [3]

Researchers became interested because alpha-MSH calms inflammation, and this small tail piece kept some of that effect in laboratory and animal tests. Unlike alpha-MSH, KPV did not act on the skin-darkening pigment receptor in most laboratory tests, which is why websites sell it as the "non-tanning" fragment. [4], [5], [6]

The key word is investigational. The FDA reviewed KPV in 2026 and found no clinical studies or human exposure data by any route. It is not an approved medicine in the United States, Canada or Australia. [1], [7], [8]

Typical KPV Protocols

Read these cautions before the numbers. No amount of KPV has ever been tested in a person, so these schedules describe what websites publish, not a dose shown to be safe or to work. In community education groups and public forums, people describe the risky steps below; each one has no evidence behind it.

• Do not stop or cut back prescribed medicine to try KPV. That includes biologics such as dupilumab or rituximab, other treatments for inflammatory bowel disease, eczema, psoriasis or arthritis, acid-reflux drugs and antibiotics. No study has tested KPV instead of, or alongside, any of them. [1]
• Not studied in under-18s, in pregnancy, while breastfeeding or when trying to conceive, or in people with a cancer history. The FDA found no reproductive, cancer or other standard safety studies. [1]
• No homemade eye drops, nasal sprays or skin mixes. Nobody has tested whether they are sterile, stable or safe.
• Micrograms and syringe units are easy to confuse. A "unit" on an insulin syringe measures liquid, not KPV, and 1 mg is 1,000 mcg. Check any amount with the reconstitution calculator (worked example below).

The most common protocol in the reviewed sources is 200–500 mcg once a day by subcutaneous injection, for about 4–8 weeks. [12], [13], [14], [15], [16], [17]

Titration Changing the amount in steps

The usual approach starts at about 200 mcg once a day for the first week, then moves to 500 mcg if it is tolerated. Some pages step up more slowly, for example 200 mcg for two weeks, 400 mcg for two weeks, then 500 mcg; one calculator site says it built that ladder itself because no source publishes one. [10], [16], [17], [18], [19]

Breaks and cycles

Sources describe 8 weeks on and 4 weeks off, 4–8 weeks on and 2–4 weeks off, or 12 weeks on and 4 weeks off. Others say breaks are not strictly needed but suggest reassessing every month. One page calls these cycle lengths a convention, and another says no study has established a cycle length. [20], [16], [21], [9], [22], [12]

Timing

Most pages simply say once a day. In community education groups, most people inject at night, and several report no difference between morning and evening.

Read the units: these amounts are micrograms (mcg); 1 mg equals 1,000 mcg. The amounts refer to KPV itself, not to the total weight of a blend such as KLOW, where KPV is only one of four peptides (see KLOW).

Each row is a complete schedule as published, so its amount and duration belong together. Low, mid and high are alternatives, not steps to move through. These schedules come from protocol websites, not from any study in people; the cited references give the full details. [1]

What about capsules?

Capsule amounts run higher than injected ones, from 200 mcg to 2 mg a day, and ready-made capsules commonly hold 250–500 mcg, taken once or twice a day. Many oral products also contain BPC-157, so the KPV amount is only part of the capsule. There is no measured conversion between oral and injected amounts, in people or animals. [24], [25], [14], [26], [1]

What about creams, nasal sprays and suppositories?

• Topical creams and gels: pages give strengths from 0.01% to 5%, usually without saying how much to apply. The strength nominated to the FDA for compounding was a 0.1% cream or gel. In human skin samples in the laboratory, almost no KPV passed through intact skin on its own. [27], [28], [23], [1], [29]
• Nasal sprays: websites mention them, but none gives an amount, and no study of nasal KPV exists in any species. [1], [15]
• Rectal suppositories or enemas: two pages give 200–500 mcg once or twice a day, with no human study behind it. [30], [27]

Where protocols differ: ceilings, cycles, routes, blends and units ↓

What is KPV commonly used for?

Most people look into KPV for a gut problem (inflammatory bowel disease, irritable bowel, reflux or bloating), an inflammatory skin condition (eczema, psoriasis, rosacea or acne), or allergy-type symptoms, including histamine intolerance and mast cell activation syndrome (MCAS). A smaller group uses it for joint or back pain. [33], [34], [35], [36]

The appeal is the idea of a gentle, targeted anti-inflammatory: a fragment of a natural hormone that settles inflammation without the skin darkening of alpha-MSH drugs or the whole-body effects of steroids. That idea comes from mouse and cell studies. No study has tested whether KPV helps any condition in people. [1], [32]

Where KPV has been tested, by topic and type of evidence. Gut inflammation: in gut-lining and immune cells, KPV was carried in by the PepT1 transporter and lowered NF-kappa-B signalling; in bowel biopsies, PepT1 levels were reported both up and down in inflammatory bowel disease, which concerns the transporter, not KPV; in mice with three types of colitis, KPV in drinking water reduced inflammation, and gel and nanoparticle forms were tested in mice and rats; tumour results were mixed, and plain oral KPV at 1 mg/kg a day gave no benefit in a 2026 study. Skin, eye and mouth: skin cells exposed to fine dust; donated skin showed no measurable passive penetration; mouse ear swelling with a capped version of KPV, rabbit corneas treated with eye drops, and rat mouth sores treated with a KPV gel. Inflammation, fever and brain: immune and airway cells; lab-stimulated blood from people with HIV; rabbit fever, mouse crystal-induced inflammation and mouse brain injury. Allergy cells and germs: bacteria and yeast in dishes, with one positive study and two that could not repeat it; donated basophils, where KPV had no effect; no animal studies found. Fat and liver: liver and fat-precursor cells; no human tissue studies; mice on a high-fat diet given KPV by mouth. People: no studies and no registered trials for any topic; two patent filings describe human use but neither is a published or registered trial.

Doserly

Where has KPV been tested?

Cell, tissue and animal research only

Gut inflammation

Cells in a dishGut-lining and immune cells: carried in by PepT1; less NF-κB signallingHuman tissue in the labBowel biopsies: PepT1 levels reported up and down in IBDAbout the transporter, not KPVAnimalsMouse colitis (3 types): less inflammation with KPV in drinking water; gels and nanoparticles in mice and ratsTumour results mixed; plain oral KPV at 1 mg/kg a day: no benefit (2026)People0 studies

Skin, eye and mouth

Cells in a dishSkin cells exposed to fine dustHuman tissue in the labDonated skin: no measurable passive penetrationAnimalsMouse ear swelling (capped KPV); rabbit cornea (eye drops); rat mouth sores (KPV gel)People0 studies

Inflammation, fever and brain

Cells in a dishImmune cells (macrophages) and airway cellsHuman tissue in the labBlood from people with HIV, stimulated in the labAnimalsRabbit fever; mouse crystal-induced inflammation; mouse brain injury (one injection)People0 studies

Allergy cells and germs

Cells in a dishBacteria and yeast: 1 positive, 2 could not repeat itHuman tissue in the labDonated basophils: KPV had no effectAnimalsNone foundPeople0 studies

Fat and liver

Cells in a dishLiver and fat-precursor cellsHuman tissue in the labNone foundAnimalsMice on a high-fat diet, KPV by mouthPeople0 studies

People: 0 studies, 0 registered trials (FDA 2026 review; ClinicalTrials.gov search, 24 Sep 2026). Tiles show evidence types, not strength of effect.

All KPV research is preclinical: cells, donated tissue and animals. The column for people is empty.

Gut problems: colitis, IBS, reflux and bloating

This is the main use, and it rests on the strongest animal research. In mice with chemically caused colitis (inflammation of the large bowel), KPV dissolved in their drinking water reduced inflammation, and in another laboratory's two colitis models, treated mice regained weight faster. In mice given a chemical that causes bowel tumors during colitis, KPV in drinking water prevented tumor formation; in mice genetically prone to bowel tumors, 13 weeks of KPV lowered gut inflammation but did not reduce tumors. [32], [37], [38]

There is a notable catch for capsules. In a 2026 mouse study, plain KPV given by mouth at 1 mg/kg a day "showed no beneficial effects" on colitis, while a chemically protected version worked at a lower dose. Much of the newer gut research tests KPV packed into nanoparticles, gels or protected forms, not the plain peptide sold online. [39], [40], [41]

People online report the full range: calmer bowels, less bloating and reflux, no change, and worse bloating, cramps or diarrhea. Most were taking other treatments at the same time. [42], [34], [26], [43] The community section gives the details.

Skin: eczema, psoriasis, rosacea and acne

Skin is the second most common use. The laboratory evidence is thin: a closely related capped version of KPV reduced ear swelling in a mouse allergy-type skin test, KPV calmed skin cells exposed to fine dust in a dish, and in rabbits, KPV eye drops sped the healing of a scraped cornea (the clear front of the eye). [4], [44], [45]

The only human claims come from patents: a 2005 application describes one person with psoriasis who applied 1 mg twice a day, and a 2026 application describes a 120-person skin-patch study that has no registry record or publication. Patent examples are the inventors' descriptions, not independent trials. [46], [47]

Public reports include eczema that cleared and stayed clear for weeks, and psoriasis or eczema that flared. [33], [48], [49], [50]

Allergies, histamine intolerance and MCAS

KPV is widely promoted for mast cells, the immune cells that release histamine in allergic reactions. We found no study that tested KPV on mast cells. The closest is a study of basophils, a related histamine-releasing blood cell, from healthy and allergic donors: full alpha-MSH calmed them, but KPV did not. [51]

Reports from people with MCAS point in both directions, from large improvements to flares, migraines and no effect after two months. In community education groups, some people use homemade nasal sprays for sinus congestion and seasonal allergies and describe fast relief, while others report nosebleeds or headaches. No study has tested nasal KPV. [35], [52]

Joint, back and nerve pain

People often combine KPV with BPC-157, TB-500 or GHK-Cu for pain, sometimes in the four-peptide blend KLOW, so any change cannot be pinned on KPV. The animal evidence is indirect: KPV reduced inflammation in mice injected in the abdomen with urate crystals (the crystals behind gout), and in rabbits it lowered fever. There are no joint or arthritis studies of KPV. [6], [53], [36], [54]

Other uses you may come across

• Brain injury and "brain fog": in mice, a single KPV injection 30 minutes after a brain injury led to smaller damage at 24 hours, although key inflammation signals did not fall. [55]
• Fat and liver: two 2026 papers found less fat build-up in liver and fat cells grown in a dish, and less weight gain in mice on a high-fat diet given KPV by mouth. [56], [57]
• Infections: early dish studies found KPV slowed staphylococcus bacteria and candida yeast, but other laboratories could not repeat the effect. [58], [59], [60]
• Vitiligo: a 2026 study used KPV only as a tag on fat bubbles (liposomes) to steer a gene treatment to pigment cells in mice; KPV itself was not the treatment. [61]

See why there is no human evidence or explore the supporting research.

Where do KPV protocols differ?

The common 200–500 mcg once-daily range hides wide disagreement. Sources differ on the ceiling, on cycling, on the route for gut problems and on how blends are counted.

How high do sources go?

On websites, the top amount ranges from 500 mcg a day, to about 1 mg, to 2 mg a day split into two injections. [12], [17], [62], [28], [31], [23]

In community education groups the spread is wider still. Some educators teach that nothing is gained above 500 mcg, others put the practical ceiling near 1 mg, some sales-linked pages go to 2 mg, and one educator says there is no tested upper limit and has seen people use 5 mg a day. Members most often report 500 mcg once daily, with a large group at 1 mg.

Every "ceiling" is an opinion. Because no human dose has been tested, there is no evidence that higher amounts work better, and none that lower amounts are proven safer.

Is the number for one dose or the whole day?

250 mcg twice a day is a 500 mcg daily total, the same total as 500 mcg once. Pages are not always clear which they mean: one labels its column "per dose" but gives the amount per day while allowing twice-daily use, and another leaves open whether its oral range is per dose or per day. [63], [12]

Once a day or twice?

Both appear. Once daily is the standard; twice daily is usually reserved for flare-ups or for amounts of 1 mg or more. Pages that explain the timing point to a "short half-life", but no study has measured KPV's half-life, so that reasoning is unsupported. [11], [17], [1]

Do sources start low?

Some do, though most pages give only a range. The common step is 200 mcg for a week, then 500 mcg. Others use 250, then 400, then 500 mcg, or a four-week climb from 200 mcg. A few start directly at 500 mcg. No source shows that a higher amount helps if a lower one did nothing. [10], [19], [18], [31]

How many weeks, and are breaks needed?

Most schedules run 4–8 weeks. Breaks range from none, to 2–4 weeks, to 4 weeks after 8 or 12 weeks, to 6 weeks off after 6 on for one blend. Reasons given, such as preventing "tolerance" or "resting receptors", have not been tested. [20], [21], [16], [64], [9]

In community education groups, practice ranges from 30-day courses to daily use for two or three years, and one group changed its guidance from 12 weeks on and 4 off to no cycling at all. Many members take a break mainly to see whether they still need it.

Capsules or injections for gut problems?

Sources split. Some say oral KPV is "unusually stable" in the gut and best for gut problems; another says digestive enzymes break it down, which is why injections are standard. [31], [17]

The research explains the split without settling it. KPV is carried into gut-lining cells by a transporter called PepT1, which supports the oral idea, and the positive mouse colitis studies gave KPV in drinking water. But a 2026 mouse study found plain oral KPV did nothing at 1 mg/kg a day, and studies disagree about whether PepT1 rises or falls in an inflamed bowel. [32], [39], [65], [66] In community education groups, some people say injections did nothing for their gut while capsules helped, and others say the reverse.

Should KPV be injected near the problem?

Not according to most sources. Educators in community education groups mostly describe KPV as acting on the whole body, so injecting near a joint or patch of skin is unnecessary; a few allow it while admitting it is unproven. No study has compared injection sites.

Should KPV be used right after an injury?

Opinions conflict, and there are no data. Some community educators suggest using KPV heavily in the first days after an injury instead of anti-inflammatory painkillers. Others advise holding it for the first few days, or for a couple of weeks after surgery, reasoning that early inflammation is part of healing.

How much KPV is in a KLOW dose?

KLOW is a blend of four peptides. The common 80 mg vial holds 50 mg of GHK-Cu and 10 mg each of BPC-157, TB-500 and KPV, so KPV is one-eighth of the blend and one-fifth of the GHK-Cu amount. [67]

That means blend doses carry much less KPV than their headline number. An injection containing 1 mg of GHK-Cu contains 200 mcg of KPV; 2.5 mg of GHK-Cu comes with 500 mcg. Some blends use other ratios: one seller's KLOW contains 3 mg of KPV per mL, giving 600 mcg in each 0.2 mL dose, five days a week for 6 weeks, then 6 weeks off. [64] Always read the amount of each ingredient on the label. See the Doserly guides to KLOW and GLOW.

Panel A: a 10 mg KPV vial mixed with 1 mL of liquid is 10 mg per mL, 100 mcg per syringe unit, so 500 mcg is 5 units; with 2 mL it is 5 mg per mL, 50 mcg per unit, so 500 mcg is 10 units; with 3 mL it is about 3.33 mg per mL, about 33 mcg per unit, so 500 mcg is 15 units. Panel B: an 80 mg KLOW vial holds 50 mg GHK-Cu and 10 mg each of BPC-157, TB-500 and KPV, so an injection with 1 mg GHK-Cu has 200 mcg KPV, about 1.67 mg GHK-Cu has about 333 mcg KPV, and 2.5 mg GHK-Cu has 500 mcg KPV. Arithmetic only, not a recommended dose.

Doserly

Same dose, different numbers

Arithmetic only; not a recommended dose

500 mcg from a 10 mg vial

10 mg vial + 1 mL liquid

Strength10 mg/mL (100 mcg per unit)500 mcg5 units

10 mg vial + 2 mL liquid

Strength5 mg/mL (50 mcg per unit)500 mcg10 units

10 mg vial + 3 mL liquid

Strength3.33 mg/mL (about 33 mcg per unit)500 mcg15 units

What is in an 80 mg KLOW vial

• GHK-Cu: 50 mg
• BPC-157: 10 mg
• TB-500: 10 mg
• KPV: 10 mg

KPV per injection is one-fifth of the GHK-Cu amount:

1 mg GHK-Cu

200 mcg KPV

About 1.67 mg GHK-Cu

About 333 mcg KPV

2.5 mg GHK-Cu

500 mcg KPV

A U-100 insulin syringe holds 100 units per mL. 1 mg = 1,000 mcg; mixing them up is a thousand-fold error. Ratios differ between blends: one contains 3 mg KPV per mL.

Syringe units measure liquid, not KPV, and a blend’s total milligrams are not its KPV amount. Check with the reconstitution calculator.

How do micrograms convert to syringe units?

On an insulin syringe, units measure liquid: a U-100 syringe holds 100 units per millilitre (mL). How much KPV each unit holds depends on how much liquid was added to the vial, a step called reconstitution.

For example, a 10 mg vial mixed with 2 mL of liquid holds 5 mg per mL, so each unit holds 50 mcg and 500 mcg is 10 units. The same vial mixed with 3 mL makes 500 mcg equal 15 units, and with 1 mL, 5 units. Copying someone else's number of units can therefore halve or double the dose, and confusing mcg with mg is a thousand-fold error. [31], [23], [18]

These mistakes are common. Public posts include "750 mg" and "500 mg" a day where micrograms were almost certainly meant, and a person who misread the units on a KLOW vial and injected about 1.3 mg of KPV a day. In community education groups, people post unit counts without saying how the vial was mixed, and one shared mixing table was labelled for one vial size but calculated for another. Doserly's reconstitution calculator works out the amount per unit for any vial and shows each step. [68], [69], [70]

The FDA's review adds one more wrinkle: public literature reports that the plain (free base) form of KPV dissolves in water only up to about 0.7 mg per mL, while the acetate salt dissolves at 5 mg per mL. Vials are rarely labelled with the form. [1]

Are single pages consistent?

Not always. One page lists both 4–8-week courses and 12 weeks on with 4 off. Another says KPV "retains the full anti-inflammatory activity" of alpha-MSH and works mainly through the pigment receptor, which the research does not support. A third cites a "no lethal dose up to 100 mg/kg" finding that has no published source, and several date the 2026 protected-KPV mouse study to 2024. One physician guide gives a molecular weight of 390.5, which does not match plain KPV (342.4). Check the units, the per-dose or per-day label and the date on every claim. [21], [31], [16], [27], [1], [39]

What happens when you stop KPV?

Nobody knows, because it has not been studied. No study has given KPV to people, and no animal study included a stopping phase, so there are no data on relapse, rebound or withdrawal. [1], [38]

Websites disagree: one KPV page recommends tapering to avoid "rebound inflammation", while general peptide pages say to simply stop and watch, or that there is no post-course symptom. None cites evidence. [71], [72], [73]

Public reports describe three patterns:

• Side effects fading. Bloating, headache, low mood and fatigue were gone about a week after stopping; a bigger appetite settled the day after each stop. [74], [75]
• Benefits lasting. Hand eczema had not returned nearly three weeks after stopping, and keratosis pilaris (rough bumps on the skin) was still gone two months later. [33], [76]
• Symptoms returning. Bloating worsened during a one-week stop, about a fifth of a shoulder's pain came back, and a person with Hashimoto's thyroiditis described rebound symptoms that were milder after tapering. [34], [77], [78]

In community education groups, the same mix appears. Reflux returned within three to seven days of running out for several members, and one member had a severe fibromyalgia flare that needed steroids 10 days after stopping. Educators there generally describe KPV as calming symptoms while it is taken, not changing the underlying disease, which is another reason not to drop prescribed treatment.

Do capsules, injections and creams of KPV behave the same way?

Almost certainly not, but nobody has measured the difference. How much of a dose reaches the blood is called bioavailability, and for KPV it has not been measured in people or animals. The FDA found no pharmacokinetic studies at all. [1]

What is known comes from separate laboratory findings:

• By mouth: gut-lining cells take KPV in through PepT1, a transporter for tiny peptides. That is why the mouse colitis studies put KPV in drinking water. Plain peptides are also broken down in the gut, which is why researchers built protected forms, and plain oral KPV failed in the 2026 mouse test. [32], [39]
• Subcutaneous injection: this is how most people take it, yet almost no KPV research used it. The animal studies gave KPV in drinking water, by injection into the abdomen or brain, or as eye drops. [32], [55], [53], [45]
• On the skin: in human skin from tissue donors, tested in the laboratory, KPV on its own did not pass through in measurable amounts. Tiny needle punctures (microneedles) let about 4.4 micrograms per square centimetre pass each hour; a mild electric current (iontophoresis) delivered about 8 times more than microneedles alone, and both together about 35 times more. A plain cream is a different thing. [29]
• On the eye: only rabbit studies exist, using drops of 1–10 mg per mL after a corneal scrape. [45]
• In the nose: no data in any species.

How long does KPV last in the body?

Half-life is the time it takes for the level in the blood to fall by half. It is not how long an effect lasts. For KPV it has never been measured, in people or animals. [1]

Figures you may see, such as "under an hour" or "up to two hours", have no study behind them. The often-quoted "66 minutes" comes from airway cells in a dish, where a marker of KPV's anti-inflammatory action reached half its peak about 66 minutes after KPV was added. That is a timing inside cells, not a blood half-life. [79], [16]

Which form of KPV is in the vial?

KPV is sold under one name but in several forms, and the FDA calls this naming confusion "a safety risk for patients" because people may receive a different substance from the one intended. [1]

Weights from the FDA review, PubChem and a chemical supplier's product sheet. [1], [80], [81]

Some older research labelled "alpha-MSH (11-13)" used the capped version, so not every study quoted for KPV tested the same molecule that vials contain. The capped version showed no antimicrobial activity in a 2018 test. [1], [4], [60]

Official identifiers only arrived recently: the FDA's substance registry created codes for the free base and the acetate on August 11, 2026. [82]

How should KPV be stored, and how long does it last?

How long mixed KPV stays usable has not been tested, so a mixed vial has no established use-by date. We found no in-use stability study of the injectable products sold online. [1]

• Powder: supplier data quoted by the FDA say the freeze-dried (lyophilized) free base keeps up to 3 years at −20 °C, 2 years at 4 °C and 3 months at 15 °C. A research-chemical supplier lists −20 °C and at least 4 years for its salt form. [1], [81]
• Mixed solution: the same supplier data give 6 months at −80 °C, 1 month at −2 °C (as printed in the review) and 1 week at 10 °C. The research supplier does "not recommend storing the aqueous solution for more than one day". [1], [81]
• How it breaks down: under acid, alkali or an oxidizing chemical, KPV breaks into a ring-shaped fragment called lys-pro-diketopiperazine. [83]

Dosing websites say something different: keep powder in the freezer, and keep a vial mixed with bacteriostatic water in the fridge (2–8 °C) for 28–30 days, away from light. Those figures follow a general peptide convention, not a KPV test, and they are far longer than the research supplier's one day. One oral-solution page says 48 hours. [31], [84], [23], [62], [85]

In community education groups, one member's newly mixed vial turned yellow, and a homemade mix of three peptides in one vial turned dark blue-black with particles within two days. Homemade nasal sprays kept for weeks have no stability or sterility data.

What do we actually know about KPV in people?

Nothing from studies. The FDA searched the medical literature, trial registries and its adverse-event databases and found no clinical studies, case reports or other human exposure data for KPV by any route. A September 2026 search of ClinicalTrials.gov for "KPV" returned zero studies. [1], [86]

Claims of human results online trace back to three things:

• Patents. A 2005 application describes single people treated on the skin, and a 2026 application describes a 120-adult skin-patch comparison with no registry record, no publication and inconsistent numbers (40 people per group in one place, 38 in another). Patent examples are claims by the inventors, not checked evidence. [46], [47]
• Different molecules. KdPT, a lookalike three-amino-acid peptide (lysine, a mirror-image proline, and threonine), was tested in a placebo-controlled trial in people with mild-to-moderate ulcerative colitis at 20, 50 or 100 mg by mouth twice a day for 8 weeks; all doses were well tolerated, and the main result was met only after additional analyses. A two-KPV molecule called CZEN-002 was registered for a dose-finding trial as a vaginal gel for yeast infections. Neither is KPV. [87], [88], [89]
• Human samples in the laboratory. Studies used donated skin, blood or cell lines. These show what happens in a dish, not in a living person. [29], [90], [51]

The FDA's adverse-event search, through December 3, 2025, found no reports, but the agency notes this cannot establish safety because such reporting is voluntary and incomplete. [1]

Why don't mouse results translate into a dose?

Most mouse colitis studies dissolved KPV in drinking water at a set strength (100 micromoles per litre), so each mouse's dose depended on how much it drank and was never measured. Other studies gave 1 mg/kg once into the abdomen, 16 micrograms/kg a day inside nanoparticles, or eye drops. None of these is a human dose, and this guide does not convert them. [32], [55], [41], [45]

What would a useful result look like?

If you are trying to judge whether anything is changing, feeling better is a weak guide on its own. Stool frequency, bleeding, bloating, itch, skin patches, pain scores and sleep are separate outcomes, and a new diet, a GLP-1 medicine, steroids or a natural lull in a flare can move all of them. Protocol pages that discuss bowel disease point to stool and blood inflammation tests and endoscopy (a camera exam of the bowel), and no KPV user has published results like these. [22], [15]

How might KPV work?

Nobody knows for certain. The FDA's 2026 review concluded that the molecular targets behind KPV's effects "remain unknown". What researchers have seen in cells and animals points to a few ideas. [1]

Getting into cells through PepT1

In gut-lining cells and immune cells grown in a dish, KPV was carried inside by PepT1, a transporter that normally absorbs tiny protein fragments from food. In mice bred without PepT1, KPV no longer prevented colitis-related tumors, which suggests it has to get inside cells to act. [32], [38]

Whether an inflamed bowel has more or less PepT1 is disputed. A 2001 study found it switched on in the colon of 10 people with ulcerative colitis or Crohn's disease but not in normal colon, while a 2014 study found it reduced in inflamed mouse bowel and in bowel samples from people with inflammatory bowel disease during flares. [65], [66]

Turning down inflammation signals inside cells

Inside cells, KPV at very low concentrations reduced the activity of NF-κB, a master switch that turns on inflammation genes, and of related signalling pathways. In airway cells it appeared to block the switch from entering the cell's nucleus. These are dish findings from a small number of laboratories. [32], [5], [79]

Not every test agreed. In one study KPV did not reduce inflammatory signals from immune cells in a dish, even though full alpha-MSH did, and in the mouse brain-injury study two key inflammation signals did not fall. [6], [55]

Does KPV cause tanning like alpha-MSH?

Laboratory studies mostly say no. Alpha-MSH darkens skin by switching on the MC1 receptor in pigment cells. KPV did not compete with alpha-MSH for that receptor, did not raise the usual receptor signal, and in immune cells did not bind the receptor even at very high concentrations. One study did see a calcium signal in cells engineered to carry the receptor, so a small interaction cannot be fully ruled out. No study has checked skin colour in people. [1], [91], [5], [92]

Does KPV calm mast cells or kill germs?

Neither claim is established. We found no mast-cell study, and in human basophils KPV did not reproduce alpha-MSH's calming effect. [51] A 2000 dish study found antimicrobial effects against staphylococcus and candida, but a 2009 report could not repeat the anti-candida effect, and a capped version of KPV showed no antimicrobial activity in 2018. [58], [59], [60]

Supporting research: the experiments behind these findings ↓

What are the risks and unanswered questions?

Is KPV safe?

Its safety in people is unknown, because it has never been studied in people. The FDA found no acute or repeated-dose toxicity studies, no tests for DNA damage, no reproductive studies and no cancer studies. It also could not rule out the immune reactions or clumping (aggregation) that peptides can cause, noting that peptides with as few as two amino acids have been shown to clump. [1]

The animal studies reported few obvious problems, but most did not look for harms: they were short efficacy tests that rarely measured side effects. The one toxicity check found, in the 2026 protected-KPV study, covered a prodrug form for seven days. [39], [1]

What problems have people reported?

Self-reports describe stomach upset (bloating, constipation, urgency, diarrhea, cramps and reflux flares), fatigue and brain fog, headache or migraine, flat mood or loss of enjoyment (anhedonia), anxiety up to a panic attack, a much bigger appetite, hives, skin flares, injection-site lumps and bruising, and flu-like symptoms with swollen glands. Single reports include an irregular heartbeat episode and chest tightness. Most people were taking other compounds too. [26], [93], [94], [95], [75], [69], [96], [97], [98], [74]

In community education groups, members also describe sudden dizziness, a racing heart or drenching sweat after a dose, facial flushing, nosebleeds from nasal use, and one case of fatigue and joint pain that lifted within hours of stopping. None of this establishes cause or frequency. The community section gives the details.

Should KPV replace prescribed treatment?

No. Nothing about KPV has been tested in people, while the medicines it is compared with have. In community education groups and public forums, people describe spacing out or stopping dupilumab, skipping rituximab infusions, weaning off arthritis or psoriasis biologics, stopping long-term acid-reflux medicines and antibiotics for rosacea, and declining a prescribed antibiotic for a sinus infection, all to try KPV. None of these choices has any evidence behind it. [1]

The better educator material in those same groups says the opposite: standard treatment comes first, peptides are at most an add-on, and nobody has studied KPV alongside biologics or other immune-suppressing drugs. The FDA also noted that approved medicines already exist for the conditions KPV was nominated for. If you are considering any change to a prescribed medicine, talk to the clinician who prescribed it first. [1]

Could product quality change the risk?

Yes. The FDA found no public information on impurity, clumping or microbiological testing for plain KPV, and the example certificate of analysis for the acetate form had no clumping or microbiological results. Different salts and even different molecules are sold under the same name. In April 2026 Health Canada named KPV among unauthorized injectable peptides it had seized, warning that such products can seriously harm health. [1], [7]

In community education groups, members report vials that turned yellow after mixing, a batch that seemed not to work, and blends whose ingredient ratios differ between sellers.

Is KPV legal? Is it FDA-approved?

Checked September 24, 2026. Rules differ by country and change quickly.

United States. KPV is not an FDA-approved drug and is not part of any approved drug. Its US history has several steps: [1]

• September 2023: the FDA placed KPV in Category 2 of its compounding list, meaning substances that may present significant safety risks. [99]
• April 2026: it was removed from that category after the pharmacy that nominated it withdrew the nomination; the FDA's safety-risk page now lists it as "nominated but withdrawn". [100], [101]
• May 2026: FDA staff recommended against adding KPV (plain or acetate) to the list of substances pharmacies may use, citing poor characterization, no human safety or effectiveness data and existing approved treatments. [1]
• July 23, 2026: the FDA's Pharmacy Compounding Advisory Committee voted 8 yes, 6 no and 1 abstention for each form. Several yes voters asked for use to be limited to the skin; no voters cited unclear uses, poor characterization and missing dose data. [102], [103]
• Since then: the vote is advice, not a decision. As of September 24, 2026 no final rule has been published, so US pharmacies still may not compound from bulk KPV under the usual rules. KPV is also not on the list for bulk outsourcing facilities. [104], [105], [106]

KPV in US regulation. 29 September 2023: placed in Category 2 of FDA’s compounding list, substances that may present significant safety risks. 22 April 2026: removed from Category 2 after the nominating pharmacy withdrew; now listed as nominated but withdrawn. 12 May 2026: FDA staff review recommends against adding plain or acetate KPV, citing no human safety or effectiveness data. 23 July 2026: the Pharmacy Compounding Advisory Committee voted 8 yes, 6 no and 1 abstention for each form; this is advice, not a decision. 24 September 2026: no final rule and no Federal Register action; compounding from bulk KPV is still not permitted under the usual 503A rules. Canada, 9 April 2026: Health Canada named KPV among seized unauthorized injectable peptides.

Doserly

KPV’s US regulatory path

Regulator records, checked 24 Sep 2026

Not to time scale.

29 Sep 2023

Placed in Category 2. FDA compounding list category for substances that may present significant safety risks

22 Apr 2026

Removed from Category 2. After the nominating pharmacy withdrew; now listed as “nominated but withdrawn”

12 May 2026

FDA staff: do not add. Review recommends against listing plain or acetate KPV: no human safety or effectiveness data

23 Jul 2026

Advisory vote 8–6–1. Pharmacy Compounding Advisory Committee: 8 yes, 6 no, 1 abstention for each form. Advice, not a decision

24 Sep 2026

No final rule. No Federal Register action; compounding from bulk KPV is still not permitted under the usual (503A) rules

Canada. 9 Apr 2026: Health Canada names KPV among seized unauthorized injectable peptides.

Dates are evenly spaced, not to time scale. Category 2 is on FDA’s list of nominated compounding substances; the advisory committee advises, the FDA decides.

A favourable advisory vote is not approval: as of 24 September 2026 there is still no final FDA rule.

Canada. Health Canada's April 9, 2026 advisory lists KPV among unauthorized injectable peptides it seized, and warns that unauthorized products can seriously harm health. [7]

Australia. KPV has no entry in the June 2026 Poisons Standard, and in May 2026 the Therapeutic Goods Administration warned about importing unapproved peptide products in general. Personal importation requires accurate labelling, and prescription-only medicines need an Australian prescription. No listing is not the same as approval. [8], [107], [108]

Europe. The European Medicines Agency lists no authorized product containing KPV. [1]

A "research use only" label does not make a product legal to sell for human use.

Is KPV banned in sport? Does it show up on a drug test?

KPV is not named on the World Anti-Doping Agency's 2026 or 2027 lists, but category S0 bans at all times any pharmacological substance that has no current approval for human therapeutic use and is not covered elsewhere on the list. KPV appears to fit that description, so athletes should treat it as prohibited. [109], [110]

A laboratory method exists to measure KPV in solutions and skin samples, but no anti-doping test or detection window for people has been published. [83]

Does KPV weaken the immune system or raise infection risk?

Nobody knows. It is promoted as calming inflammation, and in community education groups some members say they caught more colds on it, especially at higher amounts, while others say they got sick less. Laboratory antimicrobial findings are conflicting, and no study has measured infections in animals or people taking KPV. [58], [59]

Does KPV cause or prevent cancer?

Neither is known. In mice given a tumor-causing chemical during colitis, KPV in drinking water prevented bowel tumors, but it did not reduce tumors in mice genetically prone to them. Neither result says anything about people. The FDA found no cancer-safety studies. [38], [1]

In community education groups, people with a history of melanoma, breast or prostate cancer describe choosing KPV as the "safe" peptide. There is no data to support that belief either way.

Who should be especially cautious?

These groups have no safety data. That is a reason for caution, not proof of harm. [1]

• Under 18. No studies include young people. This guide is written for adults. In community education groups, KPV is discussed for teenagers' acne and children's allergies, without any evidence.
• Pregnancy, trying to conceive and breastfeeding. No reproductive studies exist in any species.
• People with a cancer history. No cancer-safety studies exist.
• People on biologics, immune-suppressing drugs or other prescribed treatment for an inflammatory disease. Nothing is known about combining them, and stopping them has real risks. See prescribed treatment.
• People with allergies, MCAS or a history of hives. Hives and allergy flares are among the reported problems, and in community education groups one person claimed a long-standing shellfish allergy had gone. Never test a known food allergy on the strength of a peptide.
• Older adults and people with heart, kidney or liver disease. No data exist, and one public report describes an irregular heartbeat episode in someone with a history of it. [98]
• People having surgery. Tell the surgical and anaesthesia team about everything you take.
• Competitive athletes. See the sport rules above.

Has KPV been tested alongside other medicines?

No. There are no interaction studies. The most common combinations, with GLP-1 medicines such as tirzepatide or retatrutide, other peptides, biologics and steroids, have never been studied together. Some people on GLP-1 medicines report that KPV seemed to bring back their appetite. Bring a complete list of everything you take to a pharmacist or doctor. [1], [75], [111]

What should be monitored while using KPV?

There is no official monitoring guidance, because no regulator has approved KPV or issued guidance for it. What can be described is what the animal studies measured, what protocol pages suggest, and which checks follow from the concerns in this guide. It is information to discuss with a clinician, not a personal testing plan. [1], [12]

None of these checks makes an untested compound safe. They show what is changing, which is what a clinician needs to judge whether to continue.

What do people in public communities report?

Public discussions include people who felt much better, people who noticed nothing, and people who stopped because of side effects, often for the same condition. Nearly everyone was also taking something else: other peptides, a GLP-1 medicine, steroids, biologics or skin treatments.

What do the positive reports look like?

Skin and gut stories are the most detailed. One person with hand eczema, using 0.5 mg twice a day and later once at night, alongside GHK-Cu and after earlier steroid creams, said the eczema cleared within two weeks and had not returned nearly three weeks after stopping. Another reported dyshidrotic eczema gone for several weeks, about six weeks after starting daily injections; no dose was given with the result. [33], [48]

For the gut, someone with IBS took 500 mcg a day for about 8 weeks while on tirzepatide and described less bloating, which got worse during a one-week stop. A person with ulcerative colitis, still on mesalazine and several other peptides, reported no visible blood and firmer stools after adding KPV. [34], [42]

A widely repeated smaller claim is that adding KPV takes the sting out of GHK-Cu injections. [113]

In community education groups, members describe relief from joint pain, reflux, palm eczema and sinus congestion, and a few track hs-CRP falling over months. Those numbers are self-reported and usually came alongside other treatments, including GLP-1 medicines; in the same groups, one parent's CRP fell sharply on a GLP-1 medicine alone.

How quickly did people notice anything?

Timelines vary from days to months. One person with a flare of ulcerative colitis described symptoms easing by day 2; someone with slow digestion noticed gut comfort by day 10; another person's acne cleared over 10 weeks while also using several other acne treatments. [114], [77], [115] In community education groups, educators suggest judging after 2–4 weeks and stopping after 8–12 weeks without change.

Does everyone notice a difference?

No. Someone with MCAS took 500 mcg twice a day for about two months and noticed nothing either way. People with SIBO (small intestinal bacterial overgrowth) reported no improvement, a KLOW user saw no change in forearm pain after four weeks, and another saw no skin change after two months. [35], [43], [116], [54], [117] In community education groups, nonresponse is common, and members more often raise the dose or blame a batch than stop.

Does getting worse first mean it is working?

Not necessarily. A few people describe a flare in the first days to two weeks, then improvement, and call it a "healing reaction". Others got worse and stayed worse: one person's psoriasis plaques appeared sooner and were more numerous over four weeks, and another's constipation and gas worsened on 500 mcg by mouth even as mood improved. [35], [74], [49], [118] One widely read public post argues that these early flares are more likely a mast-cell reaction than a sign of healing. [77] Worsening is worth taking to a clinician rather than pushing through.

What about unwanted effects?

Stomach effects are the most common: one person taking a combined BPC-157 and KPV capsule (500 mcg of each) had more bloating, urgency and abdominal pain within days. Others describe loss of enjoyment on as little as 50 mcg by mouth, anxiety building over 12 days of 500 mcg a night into a panic attack that led to an emergency visit, hives, swollen painful glands with a sore throat, and a much bigger appetite on retatrutide that settled the day after stopping each time. [26], [94], [95], [69], [96], [75]

With several compounds in most routines, these reports cannot show that KPV caused them or how often they happen.

How can you judge a recovery story?

Useful questions to ask: What else changed, including prescribed medicines, a GLP-1 medicine, diet or other peptides? Was it KPV alone or a blend? Was the change measured (photos, stool tests, blood tests) or felt? Over how long? What happened weeks later, or after stopping? Inflammatory conditions such as eczema, IBS and ulcerative colitis naturally come and go, and people usually start something new at their worst, so some improvement would be expected anyway.

These selected discussions show what people try and what they notice. They are not a survey of all users, a response rate or a substitute for controlled trials.

How does KPV compare with BPC-157, GHK-Cu, LL-37 and Melanotan II?

These are the peptides KPV is most often combined with or mistaken for. No study has compared any of them directly with KPV, so the table compares what each one is and how much human evidence exists. The route and schedule column describes what protocol sources say, not tested doses.

The real differences are in identity and evidence, not in proven results. KPV shares its three amino acids with the end of alpha-MSH, while Melanotan II copies the part that darkens skin, which is why KPV is sold as the "non-tanning" option. BPC-157 and LL-37 each have a few small human studies; KPV has none. KLOW combines KPV with BPC-157, TB-500 and GHK-Cu, and no study has tested these peptides together or against each other in people. See each guide for doses, risks and legal details.

Common questions about KPV

Is KPV the same as alpha-MSH?

No. KPV is only the last three of alpha-MSH's 13 amino acids. It lacks the central part that switches on the skin-darkening receptor, and in laboratory tests it was less potent than alpha-MSH at lowering fever and did not reproduce its effect on basophils. Findings for full alpha-MSH, such as a 2015 mouse wound-healing study that is sometimes cited for KPV, do not transfer to KPV. [1], [53], [51], [135] See how it might work.

How long does KPV take to work?

There is no established timeline, because it has not been tested in people. Public reports range from changes within days to changes over 10 weeks, effects that fade, and nothing at all; in community education groups educators suggest judging after 2–4 weeks. The mouse colitis studies ran from 2 days to about 13 weeks, which does not translate into human time. [114], [115], [32], [38] See what people reported over time.

Can KPV replace my IBD, eczema or reflux medicine?

No. KPV has never been tested in people, alone or alongside standard treatment, and approved medicines exist for these conditions. In community education groups and public forums, people describe stopping biologics, acid-reflux medicines and antibiotics to try KPV, and some describe symptoms returning within days of stopping KPV. Talk to your prescriber before changing any prescribed treatment. [1], [34] See prescribed treatment.

Is KPV the same as KdPT?

No. KdPT is a different three-amino-acid peptide, with a mirror-image proline and threonine in place of valine. It is the one that reached a human trial, an 8-week placebo-controlled study in ulcerative colitis, and the one shown to protect the gut barrier in mice. Websites sometimes cite those results as KPV evidence. [87], [136] See human research.

Can KPV be taken by mouth?

It is sold as capsules, commonly 250–500 mcg, and oral use rests on the mouse colitis studies that put KPV in drinking water and on its uptake by PepT1 in gut cells. But plain oral KPV at 1 mg/kg a day did nothing in a 2026 mouse study, and absorption has never been measured in people. [24], [32], [39] See capsules versus injections.

Should KPV be stacked with BPC-157, or used as KLOW?

These combinations are common and untested. BPC-157 and KPV are often sold together in capsules for gut problems, and KLOW adds KPV to GHK-Cu, BPC-157 and TB-500. A person who feels better on a blend cannot tell which ingredient helped, and a KLOW dose contains far less KPV than its total. [67], [26] See how much KPV is in KLOW and the Doserly guides to BPC-157, KLOW and the BPC-157 + TB-500 blend.

Is it legal to buy KPV?

It depends on where you live, and in the places checked it is not approved. It has no FDA approval, a US advisory vote in its favour has not become a rule, Health Canada has seized it, and Australia has no listing for it. A "research use only" label does not make a product legal or safe to use. [1], [104], [7], [8] See the dated legal-status summary.

Glossary

Plain explanations of the route, dosing and research terms used in this guide. Underlined terms in the text link here.

Adverse event

A harmful or unwanted medical event reported after someone used a treatment. A report alone does not prove the treatment caused it.

Aggregation

When peptide molecules clump together. Clumps can change how a product works and can trigger immune reactions.

Alpha-MSH

Alpha-melanocyte-stimulating hormone, a 13-amino-acid hormone the body makes. It darkens skin and calms inflammation. KPV is its last three amino acids.

Amino acid

A building block of proteins and peptides. KPV is made of three: lysine, proline and valine.

Anhedonia

Reduced ability to feel pleasure or enjoyment, sometimes described as feeling flat.

Animal study

Research in animals such as rats or mice. It shows what a substance does in a living body, but results in people can differ.

Bioavailability

How much of a dose reaches the bloodstream in a usable form. It has not been measured for KPV by any route.

Blend

A product that combines KPV with other peptides, such as KLOW. The blend's total amount is not its KPV amount.

BPC-157

A lab-made chain of 15 amino acids discussed for injury and gut recovery. It is often sold with KPV in capsules and in the KLOW blend.

Cell study (in vitro)

Research on cells grown in a dish. It gives early clues about biology, but it is far from proof of benefit in people.

Compounding

When a pharmacy prepares a customized medicine from individual ingredients. In the US, federal lists control which bulk ingredients pharmacies may use.

Controlled trial

A study that compares people who receive a treatment with a similar group who do not, often receiving a placebo instead. None has been done for KPV.

Course and cycle

A course is the period of repeated use, such as eight weeks. A cycle is a course plus a planned break before any further use.

Daily total

All the amounts given in one day, added together. For example, 250 mcg twice daily is a 500 mcg daily total.

Dose (amount each time)

The amount given on one occasion. A protocol lists both the dose and how often it is given.

GHK-Cu

Copper bound to a three-amino-acid peptide, used in skin care and injections. It is the largest ingredient in the KLOW blend.

Half-life

The time it takes for the measured level of a substance in the blood to fall by half. It is not the same as how long an effect lasts, and it has not been measured for KPV.

Investigational

Still being studied and not approved by a regulator, such as the FDA, to treat any condition.

Lyophilized (freeze-dried)

Dried by freezing and removing the water, leaving a powder that is mixed with liquid before use.

Mast cell activation syndrome (MCAS)

A condition in which mast cells, immune cells that release histamine, release it too easily, causing allergy-like symptoms such as flushing, hives and stomach upset.

mcg and mg

Micrograms and milligrams. 1 mg equals 1,000 mcg. KPV amounts are usually written in mcg.

NF-κB

Nuclear factor kappa B, a protein switch inside cells that turns on many inflammation genes.

Oral

Taken by mouth, as a capsule, tablet or liquid.

PepT1

A transporter protein in the gut lining that carries tiny protein fragments, and KPV, into cells.

Peptide

A short chain of amino acids. KPV is a chain of three.

Pharmacokinetics

How the body absorbs, moves, breaks down and removes a substance. It has not been studied for KPV.

Placebo

A dummy treatment with no active ingredient, used as a comparison in studies.

Preclinical research

Studies done before research in people: cell studies and animal studies.

Reconstitution

Mixing a freeze-dried powder with a liquid so it can be measured and injected. The amount of liquid sets how much peptide each unit holds.

Research use only

A label on products sold for laboratory research. It does not mean a product is approved, tested for human use or legal to sell as a medicine.

Subcutaneous (SC)

Injected into the fatty layer just under the skin. This is how most people take KPV, although almost no KPV research used this route.

Syringe units

Markings on an insulin syringe that measure volume. On a U-100 syringe, 100 units equal 1 mL. The amount of drug per unit depends on the vial's concentration.

Titration

Adjusting a dose in steps, usually starting lower and increasing if needed.

Topical

Applied to the skin, as a cream, gel or serum.

WADA

The World Anti-Doping Agency, which publishes the list of substances banned in sport.

Withdrawal and rebound

Withdrawal effects are symptoms caused by stopping a substance. A rebound is a problem returning worse than before after stopping. Neither has been studied for KPV.

Explore more of the research

Go deeper into the experiments behind the claims.

Across this guide, the citations include 29 original scientific papers that tested KPV, a KPV formulation or a closely related molecule, all preclinical (in cells, tissue samples or animals). The optional library below groups 27 of them by question. Paper counts are not counts of independent research teams: several come from the same laboratories. Registry records, reviews, websites and personal accounts are counted separately.

How this guide was researched

This guide is built from a thorough review of the sources cited throughout it: published scientific studies, trial registries, regulatory documents, patents, chemical databases and published protocol descriptions. We also reviewed public online forums and community education groups where people describe their own experiences with KPV.

The guide cites 138 sources, including 40 original scientific papers. Each type of source answers a different question. Studies show what researchers measured. Protocol descriptions show how KPV is typically used. Personal accounts show what individual people experienced. Every numbered citation links to its entry below, labeled by source type.

How this guide was made

Research and drafting were AI-assisted. Every cited source was checked against the original, and the guide was reviewed and edited by Doserly before publication. It has not had an independent clinical review, and Doserly does not currently have medical reviewers. Doserly makes a medication and health-tracking app and runs Doserly Academy, both of which are promoted in this guide. Read our editorial policy for how guides are researched, updated and corrected.

This guide is for educational purposes. It summarizes what the reviewed sources report so the research is easier to understand; it is not medical advice. For a deeper dive, or to check any point for yourself, go straight to the cited sources.

Explore the sources